Your browser doesn't support javascript.
Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era?
Katsiki, Niki; Ferrannini, Ele.
  • Katsiki N; First Department of Internal Medicine, Diabetes Center, Division of Endocrinology and Metabolism, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece.
  • Ferrannini E; C.N.R. Institute of Clinical Physiology, Pisa, Italy. Electronic address: ferranni@ifc.cnr.it.
J Diabetes Complications ; 34(12): 107723, 2020 12.
Article in English | MEDLINE | ID: covidwho-731824
ABSTRACT
Inflammation is implicated in the development and severity of the coronavirus disease 2019 (COVID-19), as well as in the pathophysiology of diabetes. Diabetes, especially when uncontrolled, is also recognized as an important risk factor for COVID-19 morbidity and mortality. Furthermore, certain inflammatory markers [i.e. C-reactive protein (CRP), interleukin-6 (IL-6) and ferritin] were reported as strong predictors of worse outcomes in COVID-19 positive patients. The same biomarkers have been associated with poor glycemic control. Therefore, achieving euglycemia in patients with diabetes is even more important in the era of the COVID-19 pandemic. Based on the above, it is clinically interesting to elucidate whether antidiabetic drugs may reduce inflammation, thus possibly minimizing the risk for COVID-19 development and severity. The present narrative review discusses the potential anti-inflammatory properties of certain antidiabetic drugs (i.e. metformin, pioglitazone, sitagliptin, linagliptin, vildagliptin, alogliptin, saxagliptin, liraglutide, dulaglutide, exenatide, lixisenatide, semaglutide, empagliflozin, dapagliflozin, canagliflozin), with a focus on CRP, IL-6 and ferritin.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / SARS-CoV-2 / COVID-19 / Hypoglycemic Agents / Inflammation Type of study: Observational study / Prognostic study / Reviews Limits: Humans Language: English Journal: J Diabetes Complications Journal subject: Endocrinology Year: 2020 Document Type: Article Affiliation country: J.jdiacomp.2020.107723

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / SARS-CoV-2 / COVID-19 / Hypoglycemic Agents / Inflammation Type of study: Observational study / Prognostic study / Reviews Limits: Humans Language: English Journal: J Diabetes Complications Journal subject: Endocrinology Year: 2020 Document Type: Article Affiliation country: J.jdiacomp.2020.107723